Business News • PR NewsWire • DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

TURKU, Finland, March 28, 2022 /PRNewswire/ -- DelSiTech Ltd, the leading silica drug delivery technology company, based in Finland and Optifye Therapeutics AG, a Swiss-based pharmaceutical company focusing on the development and commercialization of treatments for ophthalmic indications,...

View More : https://www.prnewswire.com:443/news-releases/delsitech-enters-into-an-exclusive-licensing-agreement-with-optifye-therape...

Releted News by prnewswire

VITA: Neue Werkzeug-Serie von Yard Force®

VITA: nueva serie de herramientas Yard Force® para el jardín urbano

What Entrepreneurs Should Consider When Investing in A Second Citizenship or Residency

DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

Clarivate Commits to #StandWithUkraine with Launch of Resource Center for Displaced Researchers

Yondr Group Launches 200MW Hyperscale Data Center Project in JCorp's Sedenak Tech Park, Malaysia

Argus launches non-Russian diesel price in Europe